Adcendo ApS is a biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need.
The company is advancing a clinical ADC pipeline including programs ADCE-T02 (Tissue Factor), ADCE-D01 (uPARAP), and ADCE-B05, focusing on dose escalation and expansion studies across multiple tumor indications.